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Background: The authors sought to define clinicopathologic fea-
tures associated with mutations of the epidermal growth factor
receptor (EGFR) gene in non–small cell lung cancer (NSCLC).
Methods: The authors evaluated surgically resected NSCLC tumors
for EGFR (exons 18–21) and KRAS (codons 12–13) mutations and
immunohistochemistry (EGFR, phosphorylated-EGFR, and HER2/
Neu), and correlated results with clinical outcome and patient and
disease features. After their analysis on 159 patients was completed,
they selected a second cohort of Asian patients (n  22) and
compared EGFR mutation results to place of birth and immigration
to the United States.
Results: Of 159 patients, 14 had EGFR mutations and 18 had KRAS
mutations. EGFR mutations were associated with adenocarcinoma
(p  0.002), female gender (p  0.02), never-smoking (p 
0.0001), Asian ethnicity (p 0.005), air bronchograms (p 0.004),
and multiple wedge resections (p  0.03). Although statistical
significance was not reached, a higher incidence of synchronous
primary cancers (36% versus 17%; p  0.09) and a smaller median
tumor size (11.8 cm3 versus 24.0 cm3; p  0.24) were seen. There
was no difference in disease-free survival; however, median overall
survival in patients with EGFR mutations was shorter (3.49 versus
4.29 years; p  0.85). EGFR mutation did not correlate with
immunohistochemistry. In the second cohort of 22 Asian patients,
12 (55%) had the mutation. Of interest, there was no geographic
difference in incidence of EGFR mutation. Asian women with the
EGFR mutation developed adenocarcinoma at an earlier age than
other lung cancer patients.
Conclusion: There is a distinct clinical profile for NSCLC patients
with the EGFR mutation. However, this mutation does not alter
disease-free survival and is likely attributable to an inherited sus-
ceptibility instead of an environmental effect.
(J Thorac Oncol. 2006;1: 231–239)
The epidermal growth factor receptor (EGFR) has been therecent subject of great interest in lung cancer treatment.
EGFR is overexpressed in 40 to 80% of non–small cell lung
cancer (NSCLC) patients and regulates cell proliferation, cell
survival, angiogenesis, and tumor metastasis.1 Recently, crit-
ical mutations in the adenosine triphosphate pocket of the
tyrosine kinase–binding region were reported in patients with
NSCLC.2,3 These mutations are suspected to cause constitu-
tive activation of the receptor and confer susceptibility to
EGFR tyrosine kinase inhibitors.2 EGFR exons 18 through 21
encode for structures around the adenosine triphosphate–
binding cleft within the tyrosine kinase domain.2–5 This is the
binding area for the EGFR tyrosine kinase small molecule
inhibitors gefitinib and erlotinib.
Based on the prior studies (Iressa Dose Evaluation in
Advanced Lung cancer) using EGFR tyrosine kinase inhibi-
tors, approximately 9 to 12% of European patients and 18 to
19% of Asian patients with NSCLC experienced a tumor
response to these agents.6,7 Subpopulation analyses revealed
that responders were more likely to be female and nonsmok-
ers and to have adenocarcinoma with bronchioloalveolar
features.8 However, more specific predictors of response were
unknown, as immunohistochemical studies of EGFR were
not reliable in predicting response to therapy.9 The discovery
of EGFR mutations in the tyrosine kinase domain provides
some insight into why only a small proportion of patients
benefit from EGFR targeted therapy. We sought to further
define the clinical, pathologic, and biological features asso-
ciated with the EGFR mutation in lung cancer to determine
the most likely population to benefit from screening for the
mutation.
MATERIALS AND METHODS
Methodology and Case Selection
We evaluated EGFR and KRAS gene mutations in
archived frozen and paraffin-embedded NSCLC tumor spec-
imens obtained from patients who underwent resection at The
University of Texas M. D. Anderson Cancer Center. This
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retrospective study was approved by our institutional review
board. One hundred fifty-nine tumor specimens were selected
from The University of Texas M. D. Anderson Cancer Center
Lung Specialized Program of Research Excellence Tissue
Bank based on equal numbers of squamous cell and adeno-
carcinoma histologies. Patients with medical histories of
never- and long-term former smoking were also selected to
increase the likelihood of locating tumors with the EGFR
mutation. The EGFR and KRAS mutation data from this first
cohort of 159 patients have been previously published as part
of a larger series.4
We determined the association between the mutation
analysis results with immunohistochemical expression of
EGFR, phosphorylated EGFR (p-EGFR, Y1086), and HER2/
Neu. In addition, all laboratory results were compared to
detailed clinical and pathologic disease features and outcome.
After the analysis on the first 159 patients was completed, we
selected a second group of patients (n  22) from our
archived Lung Specialized Program of Research Excellence
Tissue Bank based on Asian ethnicity to conduct the EGFR
mutation analysis. In this Asian cohort, we determined the
association between mutation status and focused clinical
information regarding smoking history, place of birth, and
time lived in the United States or Asian country.
Clinical Information Collection
Patient charts were reviewed and demographic data
were collected, including age, gender, and ethnicity. We also
collected patients’ medical history, including an extensive
history of previous cancers and cancer therapies. A break-
down of aerodigestive tract cancers compared with hemato-
logic and other solid tumors was performed. Extensive family
medical histories, including immediate family member can-
cer histories, were obtained. We also collected data on dis-
ease characteristics including pathologic confirmation of pri-
mary tumor sites, areas of clinical metastasis, histologic
pattern (including extensiveness of the bronchioloalveolar
component), level of aggressiveness (lymphatic or vascular
invasion, extracapsular invasion, microscopic lymph node
metastasis, and pleural invasion), and tumor size. Bronchi-
oloalveolar carcinoma was defined using the 2004 World
Health Organization classification for lung cancer10 and char-
acterized by the growth of neoplastic cells along preexisting
alveolar structures without evidence of stromal, pleural, or
vascular invasion and in the absence of metastasis. Both
clinical and pathologic TNM staging data were obtained.
Radiographic clinical information before surgery was col-
lected, including chest computed tomographic location of
tumor, presence of air bronchograms, quality of tumor mar-
gins (smooth or ill-defined), extension to pleura, amount of
solid component to the tumor, presence of pseudocavitation,
amount of pleural thickening, and degree of tumor spicula-
tion. Data on induction therapies used and response were
tabulated, as were type of surgical resection, adjuvant ther-
apy, and response to adjuvant therapy. Information on post-
operative complications was also collected and categorized
into cardiovascular, pulmonary, gastrointestinal, neurologic,
hematologic, or wound infection. The duration of both dis-
ease-free and overall survival from the time of diagnosis was
evaluated.
EGFR and KRAS Mutation Analysis
For the gene mutation analyses, genomic DNA was
obtained from frozen normal and primary lung tumor speci-
mens by overnight digestion with sodium dodecyl sulfate and
proteinase K digestion (Life Technologies, Inc., Rockville,
MD) at 37°C, followed by standard phenol-chloroform (1:1)
extraction and ethanol precipitation. EGFR mutation analysis
of four tyrosine kinase domain exons (18–21), that are
frequently mutated in lung cancer was performed using an
intron-based polymerase chain reaction (PCR) as previously
reported.4 All PCRs were carried out in 25 l of solution
containing 100 ng of genomic DNA using HotStarTaq DNA
polymerase (QIAGEN, Inc., Valencia, CA). DNA was am-
plified for 33 cycles at 95°C for 30 seconds, 65°C for 30
seconds, and 72°C for 45 seconds, followed by 7 minutes’
extension at 72°C. The intron-based PCR primer sequences
for exon 2 of KRAS were as previously published.4 For the
KRAS mutation analysis, DNA was amplified for 33 cycles at
95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 30
seconds, followed by 7 minutes’ extension at 72°C. All PCR
products were incubated using exonuclease I and shrimp
alkaline phosphatase (Amersham Biosciences, Inc., Piscat-
away, NJ) and sequenced directly using Applied Biosystems
PRISM dye terminator cycle sequencing method (Perkin-
Elmer Corp., Foster City, CA). All sequence variants were
confirmed by independent PCR amplifications and sequenced
in both directions.
Immunohistochemical Analysis
Immunohistochemical analyses were performed on for-
malin-fixed, paraffin-embedded specimens from surgically
resected primary lung NSCLC. Tissue microarrays were
prepared using 1-mm core sections in triplicate. Four-micron-
thick histology sections from tissue microarrays were pre-
pared for immunohistochemical analysis. Antibodies against
the EGFR clone 31G7 (Zymed, catalog no. 36-9700), Her2/
Neu (DAKO catalog no. A0485), and p-EGFR (Tyr 1086;
Zymed catalog no. 36-9700) were used as the primary anti-
bodies. Tissue slides were baked at 67°C for 30 minutes and
deparaffinized in xylene, followed by graded alcohol and DI
H2O washes, and rehydrated in TBS-t buffer. Slides were
placed in 10% DAKO Target Retrieval Solution 10 and
then steamed for 30 minutes in a 10-mM sodium citrate bath
(pH 6.0) at 95°C. The bath and slides were removed from the
steamer and cooled for 30 minutes until the temperature
reached 50°C. Endogenous peroxidase activity was then
blocked by incubating the slides for 15 minutes in a 3% H2O2
solution and 50 l of Tween-20. Nonspecific protein–protein
interaction was blocked with the addition of 200 l of 10%
fetal bovine serum/protein block solution to each slide for 35
minutes. The primary antibody was then added (200 l of
1:100 dilution with 10% fetal bovine serum/protein block
solution), and slides were incubated at room temperature for
90 minutes. Slides were washed and placed in a TBS-t bath.
DAKO Envision plus Dual-link labeled polymer was added
directly to the slides, which were then incubated for 30
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minutes. After the slides were washed, 200 l of DAKO
substrate buffer/DAB plus chromogen substrate was added to
the slides, and the slides were incubated for 5 minutes at
room temperature. Slides were immersed in H2O to stop the
reaction, counterstained in 1:3 diluted hematoxylin (DAKO
catalog no. S3301) for 6 minutes, and rinsed in H2O. Scott’s
Bluing reagent was applied for 1 minute, followed by graded
alcohol washes and then xylene incubation for 4 minutes.
Immunostaining of the cell membrane and cytoplasm for
EGFR, p-EGFR, and Her2/Neu was evaluated by light mi-
croscopy using a 20 magnification objective. A semiquan-
titative approach was used to generate a score for each tissue
core, as previously described.11 The percentage of positive
tumor and epithelial cells per focus (0–100%) was multiplied
by the dominant intensity pattern of staining (1, negative or
trace; 2, weak; 3, moderate; and 4, intense); therefore, the
overall score ranged from 0 to 400. Antibody specificity was
confirmed using blocking peptide and phosphatase incubation
experiments. For controls, we used formalin-fixed and paraf-
fin-embedded pellets from lung cancer cell lines with p-
EGFR overexpression confirmed by Western blot analysis.
Statistical Analysis
Fisher’s exact test or the chi-square test was used to
evaluate the association between EGFR mutations and clini-
cal, pathologic, and demographic features. Kaplan-Meier sur-
vival curves were estimated, and the log-rank test was applied
to assess the differences in survival distributions by EGFR
mutations and clinical and pathologic variables. The Cox
proportional hazards model was modeled to estimate the
effect of EGFR mutation, KRAS mutation, and other covari-
ates on survival.
RESULTS
Clinicopathologic Associations
Of our first cohort of 159 patients, 14 had EGFR
mutations and 18 had KRAS mutations. Patient and disease
characteristics are summarized in Table 1. Eight EGFR mu-
tations occurred in exon 19 (15- to 18-bp in-frame deletions),
one occurred in exon 20 (exon 20 insertion), and five oc-
curred in exon 21 (L858R point mutation). Table 2 provides
details on the 14 patients with EGFR mutations. Fifteen
KRAS mutations occurred in exon 12 and three occurred in
exon 13. None of the patients had both EGFR and KRAS
mutations. EGFR mutations were associated with adenocar-
cinoma histology (p  0.002), female gender (p  0.02),
never-smoker status (p  0.0001), and Asian ethnicity (p 
0.005). Four of 10 adenocarcinomas with a bronchioloalveo-
lar component demonstrated EGFR mutations (range, 20–
50%) (Figure 1 and Table 2), but none of the patients with
pure bronchioloalveolar histology (n  7) had an EGFR
mutation. All EGFR mutated lung adenocarcinomas where
mixed histologic subtype (World Health Organization Clas-
sification, 2004), with acinar predominant component in 11,
papillary in one, and solid in two.
Patients with EGFRmutations were more likely to have
undergone multiple wedge resections than were noncarriers
(28.5% versus 7.5%; p  0.03). No differences in any other
type of surgical resection were found. This was supported by
a trend toward having synchronous primary disease or lung
metastases in patients with EGFR mutations (36% compared
with 17% of those without the mutation; p  0.09). Air
bronchograms were the only significant radiographic findings
associated with the EGFR mutations (22% versus 2%; p 
0.004), as depicted in Figure 2.
There were no differences between patients with EGFR
mutations and those without in tumor location, tumor margin
characteristics, amount of extension to pleura, pseudocavita-
tion, amount of solid tumor component within the tumors,
presence of spiculation, or amount of pleural thickening.
Although statistically not significant, the median pathologic
tumor size was smaller in patients with EGFR mutations
(11.8 cm3 versus 24.0 cm3; p  0.24). There was no associ-
ation between EGFR mutation and age; clinical or pathologic
TNM stage; complications of surgery; location of the primary
tumor; pathologic features of tumor aggressiveness; or re-
sponse to adjuvant or neoadjuvant therapy. EGFR mutations
were not associated with family history of cancer, number of
immediate family members with cancer, or personal history
of cancer. Four of the patients with EGFR mutations had
prior cancers: one breast ductal carcinoma in situ, one follic-
ular lymphoma, one lung cancer, and one basal cell carci-
noma of the skin.
We conducted a limited multivariate logistic regression
analysis to determine the independent predictors for the
EGFR mutation. This analysis determined that Asian ethnic-
ity (p  0.0004), never-smoking (p  0.0001), and multiple
wedges (p  0.004) were the only features that predicted for
the EGFR mutation. However, this reduced model was hand-
icapped by the small number of patients analyzed.
Survival Analysis
The median overall survival duration in patients with
EGFR mutations was shorter than that in patients without the
mutation (3.49 years versus 4.29 years). However, this dif-
ference was not statistically significant (p 0.85) and did not
account for the effect of stage (Figure 3). After adjustment for
stage, the presence of the EGFR mutations did not appear to
affect survival duration, although the number of events was
small (figures not shown). A Cox proportional hazard model
showed that pathologic stage independently determined out-
come in our population: a higher stage conferred a hazard
ratio of 3.54 (p  0.0001).
Selected Asian Population Analysis
As we found an association between the EGFR muta-
tions and Asian ethnicity in our first patient cohort, we
selected tissue samples from an additional second cohort of
22 Asian patients from the tissue bank for EGFR analysis.
Twelve patients (55%) had the mutation (Table 3). Detailed
information on patient ethnicity, place of birth, and length of
time they had lived in the United States was known for 20
patients. Eleven of 12 patients with EGFR mutations were
born in Far East Asian nations (three from China, four from
Vietnam, one from the Philippines, and three from Korea).
The one patient born in the United States was of Greek and
Filipino descent. Six of these patients with the EGFR muta-
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tion had lived in the United States for more than 28 years, and
the other six patients had lived most of their lives in Asian
countries. Of the patients who did not have EGFR mutations,
all were born in Far East Asian countries, and more than 50%
had lived in the United States for more than 20 years (range,
21–44 years). Two patients had never lived in the United
States. Data on length of time lived in the United States and
Asia were missing for two patients. In patients who had lived
in the United States for more than 20 years (range, 21–46
years; n  12) and in patients who had lived in their home
countries most of their lives (n  8), the incidence of EGFR
mutation was similar, six of 12 (50%) and six of eight (67%),
respectively.
The median age at lung cancer diagnosis was 64 years
(range, 36–84 years) for the entire Asian cohort, with equal
numbers of men and women. The median age at diagnosis of
patients with EGFR mutations was slightly lower than in
those who did not have the mutation (58.6 versus 64 years).
A subset analysis of patient age and gender (Table 4) showed
that the median age of diagnosis of Asian women with EGFR
mutations was lower than that of Asian men who have the
mutations and Asian patients without mutations. However,
this did not reach statistical significance because of the small
number of patients involved in this study (p  0.4).
Immunohistochemistry Analysis
Tumors with EGFR mutations did not overexpress
cytoplasmic or membranous EGFR or p-EGFR (Y1086).
Patients who had EGFR mutations were more likely to have
low immunohistochemical expression of EGFR when com-
TABLE 1. Patient and Tumor Characteristics by EGFR Mutation Status
Patients with EGFR Mutation Characteristics
(n  14)
Patients without EGFR Mutation
(n  145) p Value
Age (yr)
Mean 64 66
Median 66 68
Range 45–77 40–90
Gender
Female 11 63 0.02
Male 3 82
Ethnicity
African American 0 8
Asian 3 1 0.005
White 10 129
Hispanic 1 7
Prior cancer history
Yes 5 44
No 9 101
Smoking status
Never 8 15 0.0001
Current 0 49
Former 6 81
Histology
Adenocarcinoma* 14 75 0.002
Bronchioloalveolar 0 7
Squamous cell 0 63
Pathologic stage
I 11 80
II 0 28
III 3 30
IV 0 7
Synchronous primary or lung metastasis
Present 6 25
Absent 8 120
Tumor size (cm3)
Median 11.8 24
Range 5.1–1080 0.36–2178
Overall survival (yr)
Median 3.49 4.29
*Includes 10 adenocarcinomas with bronchioloalveolar features, four with and six without the EGFR mutation.
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FIGURE 1. Microphotographs of
two representative lung adenocar-
cinomas with EGFR mutations (he-
matoxylin and eosin stained). Pan-
els a (100) and b (200) are
from a lung adenocarcinoma with
a point mutation L858R (T to G) in
exon 21 (c) and with invasive aci-
nar and solid patterns (a and b),
and without any bronchioloalveolar
component in the periphery. Panels
d (100) and e (200) were ob-
tained from a lung adenocarci-
noma having a 15–base pair (746-
750) in-frame deletion mutation in
exon 19 (f), and with a predomi-
nant invasive acinar component (e)
and some areas of bronchioloalveo-
lar-like pattern (20%) in the pe-
riphery (d).
TABLE 2. Clinicopathologic Features of Patients with Lung Adenocarcinoma EGFR Mutants from the First Cohort
Patient
Age and
Gender Ethnicity
Smoking
History
Pack-
Years
Prior
Cancer Stage
Site* of
Tumor
BAC
(%)
Air†
Bronchogram
Multiple
Lesions Surgical Resection
Type of EGFR
Mutation
72 F White Former 25 No 1B LUL 50 INEV No Lobectomy Exon 19/15-bp del
(746-750)
66 F White Former 20 No 4 RLL 30 Yes Yes Lobectomy,
multiple wedges
Exon 19/15-bp del
(746-750)
68 F White Current 80 No 4 RUL 20 INEV Yes Multiple wedges Exon 19/15-bp del
(746-750)
58 F White Current 37.5 No 1A LLL 20 No Yes Lobectomy Exon 19/15-bp del
(746-750)
66 F White Never 0 No 1B RUL 0 INEV No Lobectomy Exon 19/18-bp del
(746-751) and S752V
64 M White Never 0 No 1A RLL 0 Yes Yes Lobectomy,
multiple wedges
Exon 19/15-bp del
(746-750)
65 M Asian Former 0.8 Yes 2B RML, RLL 0 No Yes Bilobectomy Exon 19/18-bp del
(746-751) and S752I
70 F White Never 0 Yes 3A LLL 0 Yes No Lobectomy Exon 19/15-bp del
(746-750)
55 F White Never 0 No 2B RML 0 INEV No Lobectomy Exon 20
70 F White Never 0 Yes 1A LUL 0 INEV No Lobectomy Exon 21/L858R
69 M Asian Former 42 No 3A RUL 0 INEV No Lobectomy Exon 21/L858R
52 F Hispanic Never 0 No 4 RUL 0 No No Lobectomy,
multiple wedges
Exon 21/L858R
65 F White Never 0 Yes 1A RUL 0 Yes Yes Lobectomy Exon 21/L858R
45 F Asian Never 0 No 1A LUL 0 INEV No Lobectomy Exon 21/L858R
*Site of primary lung tumor location. †Presence of air bronchograms on radiographic imaging. F, female; M, male; RUL, right upper lobe; RML, right middle lobe; RLL, right
lower lobe; LUL, left upper lobe; LLL, left lower lobe; Yes, present; No, not present; INEV, not assessable because of a lack of adequate radiographic imaging; bp, base pair.
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pared with patients who did not have EGFR mutations (77%
versus 35%; p  0.02). However, there was no difference
between the two groups in level of phosphorylated EGFR
expression in both the cytoplasm and membrane. There was
also no association between EGFR mutations and the pres-
ence or level of HER2/Neu expression.
DISCUSSION
Prior clinical studies on EGFR mutations in NSCLC
report a higher frequency in women with adenocarcinoma,
Asian patients, and nonsmokers.2–5,8,12 Although our retro-
spective analysis was limited by small sample sizes and
availability of patient medical records, we were able to
confirm the clinical findings of earlier studies and also expand
the clinical profile of patients likely to harbor EGFR muta-
tions. In our study, tumors with these mutations were more
likely to be associated with air bronchograms but no other
distinguishing radiographic features. This finding should be
considered with caution, as there are so few patients evalu-
ated. Although the differences were not statistically signifi-
cant, tumors with the EGFR mutation were smaller in volume
and were more likely to metastasize to the lung or present as
synchronous tumors. Patients with EGFR mutations did not
have more previous malignancies, indicating that these mu-
tations arise de novo in the majority of cases. Also, the lack
of family history of cancer suggests that a germ-line predis-
position to acquiring these mutations is not present.
Our second cohort of Asian patients was limited in
number (n 22) and by the nature of a retrospective analysis.
However, two important observations are seen from this
FIGURE 2. Two lung tumor cases
with EGFR mutations showing inva-
sive adenocarcinoma histologic fea-
tures (mostly acinar pattern, a and
c) and corresponding chest com-
puted tomographic images (b and
f). Computed tomographic scans (b
and d) show two cases of NSCLC,
(b) right upper lobe, (d) right lower
lobe, manifesting as ill-defined
nodules. Note air bronchograms,
which correlate with EGFR mutation
status (black arrows).
FIGURE 3. Survival by presence of
EGFR and KRAS mutations.
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study. First, our analysis showed a similar incidence of EGFR
mutations in Asian patients who had lived in the United
States for more than 20 years (50%) as compared with
patients living in Asian countries most of their lives (67%).
This finding suggests that the development of a mutation in
the EGFR gene is not related to the environment but is instead
dependent on a strong genetic predisposition. This concept is
supported by the differences in the length of the EGFR intron
1 polymorphic CA dinucleotide repeat (CA-SSR 1) between
Japanese and Chinese and white and African American pop-
ulations.13 In Asian patients, the repeat lengths are consider-
ably longer than are those found in white and African Amer-
ican patients. It is of interest that the length of repeat
sequences influences EGFR gene expression, with longer
lengths leading to less gene transcription.14 The effect that
these and other genetic polymorphisms have on the rate of
mutation in the EGFR gene is unknown and provides a strong
rationale for conducting further molecular epidemiologic
studies.
Second, we report a younger median age of developing
lung cancer in Asian women with the EGFR mutation (Table
4). This result should be viewed with caution because of the
very small sample size and the lack of statistical significance.
However, this observation is important, as it suggests that the
estrogen pathway (patients were in the premenopausal age
group) may play a critical role in the early onset of carcino-
genesis in Asian patients with EGFR gene mutations. We did
not see this wide age difference between the genders in our
first cohort of predominantly white patients, but it is interest-
ing that the one Asian woman in that first cohort was 45 years
old. There may also be some variation in the effect of gender
among the Asian ethnicities. A previous report by a Japanese
group15 noted no difference in age between the women with
EGFR mutations and other male patients. Our cohort did not
include any Japanese female patients, but instead consisted of
women of Chinese, Vietnamese, Filipino, and Korean eth-
nicities. A recent report by a group from Taiwan evaluated 39
Chinese patients with EGFR mutations16 and found that the
median age in women was 62 years compared with 68 years
in men.
TABLE 3. Patient Demographics of the Asian Cohort
Patient Age
and Gender Ethnicity Place of Birth
Number of Years Lived
in the United States Smoking Status Type of EGFR Mutation
63 F Filipino Philippines 32 Never None
43 F Filipino Philippines 35 Never None
65 M Filipino Philippines 35 Current None
64 M Filipino Philippines 32 Current None
70 F Japanese Japan 44 Former None
84 M Chinese China 21 Former None
57 M Chinese China 28 Former Exon 19/18-bp del (747-752) and P753Q
68 M Chinese China 31 Former Exon 19/15-bp del (747-751)
36 F Vietnamese Vietnam 30 Never Exon 19/15-bp del (746-750)
52 M Vietnamese Vietnam 33 Former Exon 19/15-bp del (746-750)
65 M Korean Korea 39 Former Exon 19/18-bp del (746-751)
46 F Filipino/Greek United States 46 Never Exon 21/L858R
64 M Filipino Philippines Unknown Current None
63 M Taiwan Taiwan Unknown Unknown None
68 F Korean Korea 0 Never None
62 F Korean Korea 0 Never None
66 F Vietnamese Vietnam 0 Unknown Exon 19/15-bp del (746-750)
74 M Vietnamese Vietnam Lived mostly in Vietnam Current Exon 19/15-bp del (746-750)
72 F Chinese China Lived mostly in China Never Exon 21/L858R
49 F Korean Korea 0 Never Exon 21/L858R
49 F Korean Korea 0 Never Exon 21/L858R
69 M Filipino Philippines 0 Former Exon 21/L858R
M, male; F, female; bp, base pair.
TABLE 4. Age Analysis of the Asian Cohort of Patients with
and without EGFR Mutations
Gender/Age
Positive EGFR
Mutation
Negative EGFR
Mutation
Female n  6* n  5
Median (yr) 49 63
Mean (yr) 53 61
Range (yr) 36–72 43–70
Male n  6 n  5
Median (yr) 66.5 64
Mean (yr) 64 68
Range (yr) 52–74 63–84
*p  0.4.
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Although our findings of Asian women with the EGFR
mutation developing NSCLC at an earlier age are prelimi-
nary, there is compelling evidence to consider the role of
estrogen as a carcinogenic promoter in these patients. First, it
is well known that female gender is an independent risk factor
for the development of NSCLC and that premenopausal
women present with more aggressive disease.17–21 Second,
estrogens may act as tumor promoters or direct carcinogens
with DNA adduct formation.22–27 Third, Stabile et al. reported
a functional interaction between the estrogen receptor and the
EGFR pathways in NSCLC.22,28 This study also found syn-
ergistic antitumor effects with fulvestrant (an estrogen
receptor antagonist) and gefitinib (an EGFR tyrosine ki-
nase inhibitor) in murine xenografts and NSCLC cell lines.
Although this analysis did include a cell line with an
EGFR mutation (273T heterozygous point mutation at
exon 18 nucleotide 2180), conclusions on the effect of
estrogen cannot be drawn, as it is not one of the typical
mutations found in patients with NSCLC. The role of
gender on EGFR mutation is unclear at this time but should
be explored further.
In our laboratory analysis, we found low immunohis-
tochemical expression of both EGFR and phosphorylated
EGFR at site Y1086 in tumors of patients with EGFR
mutations. This apparently conflicts with the premise that the
mutations in the EGFR tyrosine kinase domain are activat-
ing mutations (L747-P753insS, L858R) with higher phos-
phorylation capability.2 Our study is not the first to report this
difference. Pao et al.5 conducted functional studies on recep-
tor mutations in exon 19 (del L747-S752, del E746-A750)
and reported low kinase activity. This was seen with both low
autophosphorylation Y1092 (p-EGFR) and low tyrosine-
phosphorylated proteins when compared with wild-type
EGFR assays. It is therefore possible that the mechanism of
EGFR tyrosine kinase inhibitor sensitivity does not occur by
means of intrinsic enhanced receptor tyrosine kinase activity
but may be caused by altered receptor-substrate–binding
capability. It is also plausible that de novo mutations in the
EGFR gene may lead to variable protein expression with
some dominant activating mutations and others that affect
substrate binding. In support of this premise, there are at least
seven different phosphorylation sites for EGFR, and the
distinct mutations appear to have preferential phosphoryla-
tion patterns. The L858R mutation is associated with phos-
phorylation at sites Y845 and Y1092, whereas phosphoryla-
tion of sites Y992 and Y1068 is associated with both the
L858R mutation and deletion of exon 19.2,5,29 Phosphoryla-
tion at sites Y1173 and Y1045 do not appear to be associated
with either mutation.29 The lack of association found in our
study between p-EGFR and EGFR mutation could be ex-
plained by the fact that our analysis focused solely on the
Y1086 phosphorylation site. We plan to further document the
preferential phosphorylation patterns of the distinct EGFR
mutations. Further molecular studies to clarify the biology of
these mutations is necessary to understand the efficacy of
tyrosine kinase inhibitor treatment and development of tumor
resistance.
CONCLUSION
In conclusion, our analysis reports the following char-
acteristics to be associated with the EGFR mutation: female
gender, Asian ethnicity, adenocarcinoma histology, never-
smoker status, presence of multiple lung lesions, and air
bronchograms on imaging. In our Asian cohort, the results
suggest an inherent and nonenvironmental susceptibility to
development of EGFR mutations. There is also some specu-
lation that Asian women with EGFR mutations may develop
adenocarcinoma at an earlier age than other patients. Further
studies on the interaction of estrogen with the EGFR pathway
are warranted, and continued efforts to define the mechanism
of tyrosine kinase inhibitor sensitivity are needed to optimize
cancer therapy.
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